Scroll To Element

Create Scroll To elements to navigate the site with small bullets on the side. You can also disable the bullet and use it for One Page Navigation

Another Banner

Create Scroll To elements to navigate the site with small bullets on the side. You can also disable the bullet and use it for One Page Navigation

Another Banner

Signup for Newsletter

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

(insert contact form here)

Home
About
Imatinib for COVID-19
News
Exvastat
Contact

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005142.

This Joint Undertaking receives support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.

IMPENTRI IMI2Follow

3 Feb

Excited to announce that the clinical trial of Impentri in patients with #COVID19 associated ARDS has been approved. Hope to recruit the first patient soon.

Reply on Twitter 1357019438252515328 Retweet on Twitter 1357019438252515328 Like on Twitter 13570194382525153282 Twitter 1357019438252515328

14 Dec

Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
https://doi.org/10.1038/s41586-020-2901-9
and https://doi.org/10.1038/s41586-020-03065-y

Reply on Twitter 1338417061589086208 Retweet on Twitter 1338417061589086208 Like on Twitter 1338417061589086208 Twitter 1338417061589086208

24 Nov

Team at University of Maryland, Baltimore recently published their protocol for study of oral imatinib in hospitalized adults with COVID-19

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04819-9#MOESM1

Reply on Twitter 1331196748015001601 Retweet on Twitter 1331196748015001601 Like on Twitter 1331196748015001601 Twitter 1331196748015001601

Home
About
Imatinib for COVID-19
News
Exvastat
Contact